Drug Use Surveillance for ADCETRIS Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"
Latest Information Update: 13 Oct 2024
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions
- Sponsors Takeda
Most Recent Events
- 13 Dec 2022 Status changed from active, no longer recruiting to completed.
- 24 Mar 2022 Status changed from recruiting to active, no longer recruiting.
- 23 Mar 2021 Planned End Date changed from 31 May 2022 to 31 Dec 2022.